Beta Bionics, Inc. - Common Stock (BBNX)

LOS ANGELES, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP, a national shareholder rights litigation firm, announces that it has filed a federal securities class action on behalf of purchasers of Beta Bionics, Inc. (“Beta Bionics” or “the Company”) (NASDAQ: BBNX) common stock between July 30, 2025 and February 24, 2026, inclusive (the “Class Period”). Beta Bionics investors have until November 3, 2026 to seek appointment as lead plaintiff of the purported class in the Beta Bionics class action lawsuit. The complaint in Holtzman v. Beta Bionics, Inc. et al., No. 2:26-cv-09999 (C.D Cal.) charges Beta Bionics and certain of the Company’s top executive officers with violations of the Securities Exchange Act of 1934.

PHILADELPHIA, Oct. 22, 2026 (GLOBE NEWSWIRE) --

NEW YORK, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) investors of the November 3, 2026 deadline involving a securities fraud class action lawsuit commenced against the Company.

NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026 (the “Class Period”).

NEW YORK and NEW ORLEANS, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NasdaqGM: BBNX) of a class action securities lawsuit.

NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Institutional and fiduciary holders of Beta Bionics stock absorbed a decline of roughly $23.09 per share, as a securities class action alleges the Company concealed a June 2025 FDA Form 483 and more than 18,000 unreported iLet customer complaints.

NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026 (the “Class Period”).

LOS ANGELES, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP, a national shareholder rights litigation firm, announces that it has filed a federal securities class action on behalf of purchasers of Beta Bionics, Inc. (“Beta Bionics” or “the Company”) (NASDAQ: BBNX) common stock between July 30, 2025 and February 24, 2026, inclusive (the “Class Period”). Beta Bionics investors have until November 3, 2026 to seek appointment as lead plaintiff of the purported class in the Beta Bionics class action lawsuit. The complaint in Holtzman v. Beta Bionics, Inc. et al., No. 2:26-cv-09999 (C.D Cal.) charges Beta Bionics and certain of the Company’s top executive officers with violations of the Securities Exchange Act of 1934.

Promise versus reality: the lawsuit contends Beta Bionics promoted "superior clinical outcomes" for its iLet insulin pump while a June 2025 FDA Form 483 documenting more than 18,000 unreported customer complaints stayed out of public view, and BBNX shares later fell roughly $23.09 from their Class Period high.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Notice to Pension Funds, Asset Managers, and Fiduciaries

NEW YORK, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026 (the “Class Period”).

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW ORLEANS, Oct. 15, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 3, 2026 to file lead plaintiff applications in a securities class action lawsuit against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NasdaqGM: BBNX), if they purchased or otherwise acquired the Company’s common stock between July 30, 2025 and February 24, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California.

LOS ANGELES, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP, a national shareholder rights litigation firm, announces that it has filed a federal securities class action on behalf of purchasers of Beta Bionics, Inc. (“Beta Bionics” or “the Company”) (NASDAQ: BBNX) common stock between July 30, 2025 and February 24, 2026, inclusive (the “Class Period”). Beta Bionics investors have until November 3, 2026 to seek appointment as lead plaintiff of the purported class in the Beta Bionics class action lawsuit. The complaint in Holtzman v. Beta Bionics, Inc. et al., No. 2:26-cv-09999 (C.D Cal.) charges Beta Bionics and certain of the Company’s top executive officers with violations of the Securities Exchange Act of 1934.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026 (the “Class Period”).

NEW YORK and NEW ORLEANS, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NasdaqGM: BBNX) of a class action securities lawsuit.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Disclosure under scrutiny: the lawsuit contends Beta Bionics' SEC filings described the FDA's Warning Letter as flagging "non-conformities" in its Quality Management System while allegedly omitting that hundreds of unreported iLet complaints involved life-threatening hypoglycemia.